Oxiracetam in dementia: a double‐blind, placebo‐controlled study

@article{Bottini1992OxiracetamID,
  title={Oxiracetam in dementia: a double‐blind, placebo‐controlled study},
  author={G. Bottini and G. Vallar and S. Cappa and G. Monza and E. Scarpini and P. Baron and A. Cheldi and G. Scarlato},
  journal={Acta Neurologica Scandinavica},
  year={1992},
  volume={86}
}
A multicentre, double‐blind, between‐patient study was carried out to evaluate the efficacy and tolerability of oxiracetam (800 mg tablet), in comparison with placebo, each given twice daily for 12 weeks to patients suffering from primary degenerative, multi‐infarct or mixed dementia. Efficacy was assessed by a neuropsychological battery (simple reaction time, controlled associations, short story, Raven's Progressive Matrices, token test, digit span, word list learning), administered at the… Expand
Practice parameter: Management of dementia (an evidence-based review)
TLDR
The uncorrected, first-pass data analysis revealed no significant beneficial effect of vitamin E and there were no significant effects on cognitive measures in the study, certainly raising the possibility that any poorly defined effect of Vitamin E on the outcome measure may have nothing specifically to do with AD. Expand
Practice parameter: Management of dementia (an evidence-based review)
TLDR
Cholinesterase inhibitors benefit patients with AD, although the average benefit appears small; vitamin E likely delays the time to clinical worsening; selegiline, other antioxidants, anti-inflammatories, and estrogen require further study. Expand
Comparative toxicity and toxicokinetic studies of oxiracetam and (S)-oxiracetam in dogs
TLDR
The 13-week toxicokinetics study indicated that, in the (S)-ORT group, the time to peak concentration was delayed, elimination half-life extended, and apparent volume of distribution increased compared with the ORT group. Expand
A Review of Quality of Life in Alzheimer’s Disease
TLDR
A systematic review was carried out to include the published data on QOL assessment tools and instruments that claim to measure quality of life in dementia, and decided to present the resulting review in 2 parts that correspond to the 2 main groups into which the instruments were categorised. Expand
A Review of Quality of Life in Alzheimer’s Disease
TLDR
A systematic review was carried out to assess the published data (and some unpublished data) on QOL assessment tools and instruments that claim to measure quality of life in dementia and was unable to identify any validated methods of assessing the quality oflife of both patients with dementia and their carers at the same time. Expand
Treatment of Alzheimer ’ s Disease : A Comparison of Racetam Compounds and Current Medication
The purpose of this paper is to examine whether oxiracetam and aniracetam are more effective than donepezil and tacrine, two drugs currently used to treat Alzheimer’s disease. Past research suggestsExpand
Effects of oxiracetam on organic brain syndrome following activation of the high-affinity choline uptake system: A neurochemical analysis of the cerebrospinal fluid of four patients
TLDR
Following oxiracetam treatment, average ACh levels in CSF decreased significantly, and there was a concomitant improvement in the clinical evaluation (SCAG). Expand
DRUGS INFLUENCING COGNITIVE FUNCTION
Drugs can inOuence cognitive function in several different ways. The cognitrve enhancers or nootropics have become a major issue in drug development during the last decade. Nootropics arc defined asExpand
Nootropic Drugs: The Gap Between Preclinical and Clinical Results
TLDR
A short overview of the state of the art of the pharmacology and clinical trials on the nootropics. Expand
Pharmacological Treatment of Dementia: Summary
TLDR
This report is a systematic evaluation of the evidence for pharmacological interventions for the treatment of dementia in the domains of cognition, global function, behavior/mood, quality of life/activities of daily living (ADL) and caregiver burden. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 25 REFERENCES
A double‐blind, placebo‐controlled study with oxiracetam in demented patients administered the Luria‐Nebraska Neuropsychological Battery
A formal multicenter, double‐blind, between‐patient trial was carried out to evaluate the efficacy and tolerability of oxiracetam (OXIR) (800‐mg tablets), in comparison with placebo, each given twiceExpand
Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study.
TLDR
A significantly different effect, in favor of oxiracetam, was observed in the three main efficacy criteria (i.e. IPSC-E, Blessed Dementia Scale and NMIC total scores), and confirmed by descriptive analyses carried out on some subitems of the scales used. Expand
Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.
TLDR
In the present population of patients with mild to moderate degree dementia, 1600 mg/day of oxiracetam was effective in enhancing both attentional activities and other, more complex, neuropsychological functions. Expand
Oxiracetam in the treatment of multi-infarct dementia
1. Initial clinical trials in approximately 200 patients with dementias of diverse etiology suggested that oxiracetam, a structural analogue of the nootropic piracetam, was of some benefit in theExpand
Activity of Oxiracetam in Patients with Organic Brain Syndrome: A Neuropsychological Study
TLDR
In OBS patients with a mild to moderate degree of cognitive impairment, oxiracetam showed to improve cognitive functions, logical performance, and attention and other behavioral and functional parameters were also positively modified. Expand
Experimental Behavioral Studies with Oxiracetam on Different Types of Chronic Cerebral Impairment
Summary: Oxiracetam (4-hydroxy-2-oxo-1-pyrrolidine acetamide) is a novel compound effective in improving learning and memory in normal animals as well as in animals with acute cerebral impairmentExpand
Effect of Oxiracetam and Piracetam on Central Cholinergic Mechanisms and Active‐Avoidance Acquisition
TLDR
It is indicated that oxiracetam enhances the activity of the septohippocampal cholinergic pathways, and to a lesser extent, of the corticalCholinergic network. Expand
Cerebral blood flow in dementia
To the Editor: Dr. Rogers et all demonstrated a decrease in cerebral blood flow (CBF) long before there was clinical evidence of vascular dementia, but CBF was relatively preserved in patients withExpand
Oxiracetam prevents electroshock-induced decrease in brain acetylcholine and amnesia.
TLDR
The hypothesis that oxiracetam may prevent the disruption of the conditioned response by acting on cortical and hippocampal cholinergic mechanisms is supported. Expand
Clinical diagnosis of Alzheimer's disease
TLDR
The criteria proposed are intended to serve as a guide for the diagnosis of probable, possible, and definite Alzheimer's disease; these criteria will be revised as more definitive information becomes available. Expand
...
1
2
3
...